Arctic Bioscience, a biotech company developing and commercializing nutraceutical and pharmaceutical products based on the unique properties of bioactive marine compounds has appointed
"Arctic Bioscience is in a phase focused on expanding the commercial and strategic opportunities for our pharma and nutra activities. This includes developing our current allliances as well as forging new strategic alliances for further expansion and the execution of the upcoming Phase II study for the psoriasis drug candidate. Christer's experience from capital markets and from managing and advising growth companies will provide us with the skill set required to drive long-term stakeholder value creation," said
"I am excited about the opportunity to lead the further development and commercial expansion of Artic Bioscience and its activities to release the huge potential in the pharmaceutical and nutraceutical business", said
"Developing a high competence company in Ørsta, taking it from a small nutraceutical start-up in 2018 to a listed biotech company in 2021, has been a really rewarding journey.
Arctic Bioscience is a company like no other, using cutting edge technology to turn immature herring roe into nutraceuticals and medicines for the future. I wish my successor and the ABS team all the best in continuing this thrilling journey, " said Ole Arne Eiksund
"The Board would like to thank
For further information, please contact:
Chair of the Board of
Phone: +47 90 85 93 97
Email: harald.nordal@online .no
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing nutraceutical products based on the unique properties of bioactive marine compounds. The company nutraceutical brand Romega contains lipids that are essential to maintain cell membranes, contributing to normal functioning of brain, heart, and vision. Romega is sold globally as bulk ingredients to other companies making dietary supplements, and as finished goods.
The company is developing HRO350 - a novel investigational drug candidate with herring roe as raw material. HRO350 is being developed for treatment of mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.
https://news.cision.com/arctic-bioscience-as/r/arctic-bioscience---christer-valderhaug-appointed-new-ceo,c3485966
https://mb.cision.com/Main/20422/3485966/1520229.pdf
(c) 2022 Cision. All rights reserved., source